Ligand Pharmaceuticals Inc
LGND
View Detailed Chart
201.660USD
+1.300+0.65%
Close 03/24, 16:00（ET）Quotes delayed by 15 min
3.98BMarket Cap
32.88P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.65%
5 Days
-4.42%
1 Month
+6.70%
6 Months
+19.35%
Year to Date
+6.66%
1 Year
+80.59%
View Detailed Chart
TradingKey Stock Score of Ligand Pharmaceuticals Inc
Currency: USD Updated: 2026-03-24Key Insights
Ligand Pharmaceuticals Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 4 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 244.50.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Ligand Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Ligand Pharmaceuticals Inc Highlights
StrengthsRisks
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 104.16% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 268.09M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is 32.88, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 20.48M shares, decreasing 1.52% quarter-over-quarter.
Held by Ray Dalio
Star Investor Ray Dalio holds 4.21K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.11.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
244.500
Target Price
+19.38%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Ligand Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Ligand Pharmaceuticals Inc Info
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
Ticker SymbolLGND
CompanyLigand Pharmaceuticals Inc
CEODavis (Todd C)
Websitehttps://www.ligand.com/
Related Instruments
-0.83%
+0.56%
-0.06%
+0.93%
+0.60%
+0.13%
+0.35%
-0.38%
+0.56%
+0.71%
+0.19%
+0.83%
+1.85%
+0.68%
-0.58%
0.00%
+0.40%
+0.70%
+0.61%
+1.01%Popular Symbols
251.640
+0.150 (+0.06%)
175.200
-0.440 (-0.25%)
71199.120
+1135.930 (+1.62%)
301.050
+6.260 (+2.12%)
2170.090
+24.110 (+1.12%)
383.030
+2.180 (+0.57%)
4553.910
+83.410 (+1.87%)
88.869
+0.766 (+0.87%)
1.159
-0.001 (-0.12%)
159.015
+0.320 (+0.20%)
